HN21C0976

Development of peptide T against sarcopenia in a form of muscle-specific delivered fusion peptides

Asan Medical Center

METABOLIC | **Hit**

Product Type	Peptide Product
Indication	1st indication: Rare muscle diseases(such as Duchenne muscular dystrophy) 2nd indication: Sarcopenia
Target	Myoblast
MoA(Mechanism of Action)	Peptide T → Binding to cell surface receptor → Stimulation of myogenesis → Targeted therapy for sarcopenia
Competitiveness	• The goal is to develop specifically delivered peptides to muscles with enhanced efficacy through peptide modifications and fusions. • The drug will be developed as a drug for rare muscle diseases such as Duchenne muscular dystrophy, and then its clinical use will be expanded to a treatment for sarcopenia. • No pathological or hematologic abnormalities were observed in trnasgenic mice overexpressing peptide T precursor protein, suggesting that the potential for unexpected side effects of peptide T-based therapeutics is very low. In addition, the development of a peptide specifically delivered to muscle may maximize their therapeutic efficacy and eliminate their potential side effects.
Development Stage	Hit
Route of Administration	Parental-subcutaneous

kddf_bd@kddf.org
KDDF Business Development Team